We are recruiting participants for our new CHARM study, titled “cfDNA in Hereditary And High-Risk Malignancies (CHARM) 2: Evaluating the Performance of a cfDNA Blood Test for Early Cancer Detection”
We are currently recruiting participants at the University Health Network in Toronto who fulfill the following criteria:
1. Individuals with one of the following Hereditary Cancer Syndromes:
- Hereditary Breast and Ovarian Cancer (BRCA1, BRCA2 genes)
- Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM genes)
- Li-Fraumeni Syndrome (TP53 gene)
- Neurofibromatosis Type 1 (NF1 gene)
- Hereditary Diffuse Gastic Cancer (CDH1 gene)
2. Individuals without a personal history of cancer diagnosed and treated within 3 years prior to their enrolment in this study. If you have a personal history of cancer and are interested in participating, treatment must have been completed at least 3 years prior to study enrolment.
Information about the CHARM2 study can be found here.
If you fulfill the above criteria and are interesting in participating in this study, please contact us.